Document:

EX-10.9

 Exhibit 10.9 

ERASCA, INC. 

SCIENTIFIC ADVISORY BOARD AGREEMENT 

THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (this
“Agreement”) is made and entered into as of August 15, 2020 (the “Effective Date”), by and between ERASCA, INC., a Delaware
corporation (the “Company”), having its principal place of business at 10835 Road to the Cure, Suite 140, San Diego, CA 92121, and MICHAEL D. VARNEY, PH.D., an individual
with an address at 709 N. Granados Ave., Solana Beach, CA 92075 (the “Advisor”). The Company and the Advisor may be referred to herein individually as “Party” or collectively, as
“Parties.” 
 RECITAL 

As part of its ongoing program of research and development, the Company desires to retain distinguished scientists and other qualified
individuals to advise the Company with respect to its technology strategy. In furtherance thereof, the Company desires to retain Advisor as a member of its Scientific Advisory Board as described below, and the Company and Advisor desire to enter
into this Agreement to effect such retention. 
 AGREEMENT 

In consideration of the mutual covenants set forth below, the Parties hereby agree as follows: 

1. SCIENTIFIC ADVISORY BOARD AND CONSULTING
SERVICES. Commencing on the Effective Date, the Company hereby retains Advisor, and Advisor hereby agrees to serve, as a member of the Company’s Scientific Advisory Board (the “SAB”) and
as a consultant to the Company. As member of the SAB and consultant, Advisor agrees to devote Advisor’s best efforts to provide the services as follows: (a) attending meetings of the Company’s SAB; (b) performing the duties of an
SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company
and assisting in developing strategies for achieving such goals, and providing advice in the Company’s scientific research and product development activities; and (c) providing consulting services to the Company at its request, including a
reasonable amount of informal consultation over the telephone or otherwise as requested by the Company. The services to be provided by Advisor hereunder are referred to collectively herein as the “Services.” Advisor shall
provide Services to the Company as reasonably requested by the Company. Advisor’s consultation with the Company will involve oncology targets covered by the Company’s pipeline to shut down the RAS/MAPK pathway (including SHP2, KRAS, EGFR
and ULK) as well as other targets that the Company is evaluating that the Parties mutually conclude do not conflict with Advisor’s current responsibilities (collectively, the “Field”), and requires the application of
unique, special and extraordinary knowledge that Advisor possesses in the Field. 
 2. COMPENSATION.

 2.1. As compensation for performing the Services, the Advisor, subject to approval of the Company’s board of directors, will be
granted stock options to purchase 150,000 shares of the Company’s common stock at an exercise price per share equal to the fair market value per share of the Company’s common stock on the date of grant (the “stock
options”). The stock options will be granted pursuant to the Company’s equity incentive plan (the “plan”). The stock options will be subject to the terms and conditions of the plan and Advisor’s stock
option agreement, and will include an early-exercise feature at Advisor’s election. The stock options will vest over a four-year vesting schedule. For so long as Advisor continues to perform the services hereunder and through each vesting date,
the stock options shall vest as to 25% of the shares underlying the award on the one year anniversary of the vesting commencement date (as defined and set forth in the stock option grant) and as to 1/48th of the shares underlying the award on a
monthly basis thereafter. 

 2.2. In addition, the Company shall pay Advisor at the rate of $650 per hour for
Services that exceed the scope of work of general members of the SAB, as mutually agreed by the Company and Advisor. If requested by the Company, Advisor shall provide an invoice or similar documentation of work performed under this Section 2.2
on a monthly basis, including the number of hours worked and general description of work performed by day. 
 3.
INDEPENDENT CONTRACTOR. The Parties understand and agree that Advisor is an independent contractor and not an employee of the Company. Advisor has no authority to obligate the Company by contract
or otherwise. Advisor will not be eligible for any employee benefits, nor will the Company make deductions from Advisor’s fees for taxes (except as otherwise required by applicable law or regulation). Any taxes imposed on Advisor due to
activities performed hereunder will be the sole responsibility of Advisor. 
 4. OTHER
ACTIVITIES. The Company acknowledges that Advisor may serve as a member of third-party boards of directors and scientific advisory boards or similar appointments as well as engage in consulting and advisory services
to third parties, and nothing in this Agreement is intended to limit Advisor’s other business, educational or philanthropic activities, subject to compliance with the non-disclosure (Section 5),
intellectual property (Section 6) and non-competition/nonsolicitation (Section 7) provisions set forth below. 

5. RECOGNITION OF COMPANY’S RIGHTS;
NONDISCLOSURE. Advisor recognizes that the Company is engaged in a continuous program of research and development respecting its present and future business activities. Advisor agrees as follows: 

5.1. At all times during the term of Advisor’s association with the Company and thereafter, Advisor will hold in strictest confidence and
will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except to the extent such disclosure, use or publication may be required in direct connection with Advisor’s performing requested
Services for the Company or is expressly authorized in writing by an officer of the Company. 
 5.2. The term “Proprietary
Information” shall mean any and all trade secrets, confidential knowledge, know-how, data or other proprietary information or materials of the Company. By way of illustration but not limitation,
Proprietary Information includes: (i) inventions, ideas, samples, prototypes, processes, compositions, formulations, compounds, techniques, patent disclosures, patent applications, devices, hardware, software, electronic components and
materials, and procedures for producing any such items, as well as data, know-how, improvements, inventions, discoveries, developments, designs and techniques; and (ii) information regarding plans for
research, development, new products, marketing and selling activities, business models, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (iii) information regarding the skills and
compensation of employees or other consultants of the Company. 
 5.3. In addition, Advisor understands that the Company has received and in
the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it
only for certain limited purposes. During the term of Advisor’s association and thereafter, Advisor will hold Third Party Information provided to Advisor by or on behalf of Company in the strictest confidence and will not disclose or use Third
Party Information, except in connection with Advisor’s performing requested Services for the Company, or as expressly authorized in writing by an officer of the Company. 

  
 2 

 6. INTELLECTUAL PROPERTY
RIGHTS. 
 6.1. Advisor agrees that any and all ideas, inventions, technologies, discoveries, improvements,
know-how and techniques that the Advisor conceives, reduces to practice or develops during the term of this Agreement, alone or in conjunction with others, as a result of performing the Services for the
Company under this Agreement (collectively, the “Inventions”) shall be the sole and exclusive property of the Company. 

6.2. Advisor hereby assigns to the Company his entire right, title and interest in and to all Inventions. Upon Company’s reasonable
request and at Company’s expense, Advisor will perform other activities necessary to effect the intent of this Section 6.2. 

6.3. Advisor further agrees to cooperate and provide reasonable assistance to the Company to obtain and from time to time enforce United States
and foreign patents, copyrights, and other rights and protections claiming, covering or relating to the Inventions in any and all countries. 

6.4. Advisor agrees to submit to the Company any proposed publication that contains Proprietary Information, Inventions or work performed by
Advisor for the Company hereunder. Advisor further agrees that no such publication shall be made without the prior written consent of the Company, which consent shall not be unreasonably withheld. 

7. NONCOMPETITION AND NONSOLICITATION OF
EMPLOYEES. 
 7.1. During the term of this Agreement, Advisor will not, without the prior consent of the
Company, engage in any commercial business activity that competes in any way with any business then being conducted or planned by the Company in the Field, except that Advisor may continue the affiliations set forth in Exhibit A. The
foregoing shall not prevent Advisor from conducting any academic research, teaching or related non-commercial activity. 

7.2. During the term of this Agreement and for one (1) year after its termination, Advisor will not personally or through others recruit,
solicit or induce any employee or consultant of the Company to terminate his or her employment with the Company. 
 7.3. If any restriction
set forth in Sections 7.1 and 7.2 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall
be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable. 

8. NO CONFLICTING OBLIGATION. 

8.1. Advisor represents that Advisor’s performance of all of the terms of this Agreement and the performing of the Services for the
Company do not and will not breach or conflict with any agreement with a third party, including, without limitation, any entity listed on Exhibit A. 

8.2. Advisor hereby agrees not to enter into any agreement that conflicts with this Agreement. 

  
 3 

 9. NO IMPROPER USE OF
MATERIALS. Advisor agrees not to bring to the Company or to use in the performance of Services for the Company any materials or documents of a present or former employer of Advisor, or any materials or documents
obtained by Advisor from a third party under an obligation of confidentiality, unless such materials or documents are generally available to the public or Advisor has authorization from such present or former employer or third party for the
possession and unrestricted use of such materials. Advisor understands that Advisor is not to breach any obligation of confidentiality that Advisor has to present or former employers or clients, and agrees to fulfill all such obligations during the
term of this Agreement. 
 10. TERM AND TERMINATION. 

10.1. This Agreement, and Advisor’s Services hereunder, shall commence on the Effective Date and shall continue for an initial term of one
(1) year after the Effective Date, unless earlier terminated as provided below. At the end of such initial term, this Agreement will automatically be extended for an additional period or periods of one (1) year each, unless the Advisor or
the Company shall have given to the other written notice to the contrary at least thirty (30) days prior to the commencement of such additional period. 

10.2. Advisor or the Company may terminate this Agreement at any time by giving no less than thirty (30) days prior written notice to the
other Party. 
 10.3. The obligations set forth in Sections 5, 6, 7 and 10 through 16 will survive any
termination or expiration of this Agreement. Upon termination of this Agreement, Advisor will promptly deliver to the Company all documents and other materials of any nature pertaining to the Services, together with all documents and other items
containing or pertaining to any Proprietary Information. 
 11. ASSIGNMENT. The rights and liabilities
of the Parties hereto shall bind and inure to the benefit of their respective successors, heirs, executors and administrators, as the case may be; provided that, as the Company has specifically contracted for Advisor’s Services, Advisor may not
assign or delegate Advisor’s obligations under this Agreement either in whole or in part without the prior written consent of the Company. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all
or substantially all of the Company’s business. Any assignment not in accordance with this Section 11 shall be void. 

12. LEGAL AND EQUITABLE REMEDIES. Because Advisor’s
Services are personal and unique and because Advisor may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by seeking
injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement. 

13. GOVERNING LAW; SEVERABILITY. This Agreement shall be governed by and
construed according to the laws of the State of California, without regards to conflicts of laws rules. If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and the
remainder of this Agreement shall continue in full force and effect. 
 14. COMPLETE UNDERSTANDING;
MODIFICATION. This Agreement, and Exhibit A, constitute the final, exclusive and complete understanding and agreement of the Parties hereto and supersedes all prior understandings and agreements. Any waiver,
modification or amendment of any provision of this Agreement shall be effective only if in writing and signed by the Parties hereto. 
 15.
NOTICES. Any notices required or permitted hereunder shall be given to the appropriate Party at the address listed on the first page of this Agreement, or such other address as the Party shall specify in writing
pursuant to this notice provision. Such notice shall be deemed given upon personal delivery to the appropriate address or three days after the date of mailing if sent by certified or registered mail. 

  
 4 

 16. COUNTERPARTS. This Agreement may be executed in one
or more counterparts each of which will be deemed an original, but all of which together shall constitute one and the same instrument. 

[Signature Page Follows] 

  
 5 

 IN WITNESS WHEREOF, the
Parties hereto have executed this Agreement as of the date first written above. 
  

									
	Erasca, Inc.	  		  	MICHAEL D. VARNEY, PH.D.
				
	By:	  	 /s/ Jonathan Lim
	  		  	 /s/ Michael Varney

		  	Name:	  	Jonathan E. Lim, M.D.	  		  	
		  	Title:	  	Executive Chairman	  		  	

 SIGNATURE PAGE TO SCIENTIFIC
ADVISORY BOARD AGREEMENT 

 EXHIBIT A 

Affiliations 
 [Please list any
potentially competitive engagements here so that Erasca can evaluate and the parties agree upon best protocol to avoid conflicts.] 
 1) “Senior
Advisor,” Frazier Healthcare Ventures. This is an advisory role. 
 2) Scientific Advisory Board Member, Turning Point. 

3) Sporadic consulting on an individual basis (as time permits) with small companies.EX-10.10

 Exhibit 10.10 

 
 

 
 November 5, 2020 
 Wei
Lin, M.D. 
  

	Re:	 Employment Offer Letter 

Dear Wei: 
 Erasca, Inc. (the
“Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”). 

• DUTIES. You shall serve and shall perform such duties as are customarily associated
with the position of Chief Medical Officer, and such other duties consistent with such position as are assigned to you by your supervisor. You will report directly to Jonathan Lim, M.D., Chairman and CEO. You shall perform your
services on a full-time basis. We understand that you will work remotely in the interim with a commitment to fully relocate to San Diego, CA within 12 months of your commencement of employment with the Company and will make reasonable efforts to
travel to the Company’s headquarters as needed for key meetings and activities. This is an exempt position.  
 •
START DATE. Your start date will be on or after TUESDAY, JANUARY 5, 2021 (“Start Date”). This offer, if not accepted, will expire at the close of business
on MONDAY, NOVEMBER 9, 2020.  
 • COMPENSATION. Your initial compensation will be as
follows: 
  

	 	•	 	 BASE SALARY. The semi-monthly pay for this position is $17,916.67,
equivalent to an annual base salary of $430,000 less applicable taxes and other withholdings according to the Company’s normal payroll practices. Your base salary will be subject to review for potential increase at least annually.

  

	 	•	 	 ANNUAL BONUS. Commencing in 2021, you may also be eligible for a bonus of up
to 35% of your base salary (with 35% being your “Target Bonus Amount”), prorated for days worked based on your Start Date if your Start Date is delayed beyond January 5, 2021, subject to the approval by the Board
of Directors and achievement of corporate and individual performance goals. Any bonus will be paid no later than the March 15 after the end of the calendar year to which the bonus relates. 

 

	 	•	 	 STOCK OPTIONS. Subject to approval of the
Company’s board of directors, as soon as reasonably practicable following your Start Date, you will be granted stock options to purchase 1,375,000 shares of the Company’s common stock (which represents approximately 1.29% of
the Company’s fully diluted, outstanding common stock as of the date hereof) at an exercise price per share equal to the fair market value per share of the Company’s common stock on the date of grant (the

	 	 
“Stock Options”). The Stock Options will be granted pursuant to the Company’s 2018 Equity Incentive Plan (the “Plan”). The Stock Options will
be subject to the terms and conditions of the Plan and your stock option agreement, which will be consistent in all respects with the terms in this Agreement. The Stock Options will vest over a four year vesting schedule, with 25% of the total
number of shares subject to the award shall vest on the one-year anniversary of the Start Date , and 1/48th of the total number of shares subject to the
award shall vest on each monthly anniversary thereafter, subject to your continued employment or service with the Company on each vesting date or the date of any applicable accelerated vesting. You may elect to “early exercise” some or all
of the Stock Options prior to vesting, and following any such “early exercise,” any restricted shares may be transferred to a trust established for the benefit of one or more immediate family members as permitted under the Plan (subject to
execution of appropriate transfer paperwork and agreement). The Stock Options will be incentive stock options to the maximum extent permitted by applicable law, and you will have at least 3 months following your termination for any reason to
exercise any vested portion of the Stock Options. The Stock Options will be eligible for accelerated vesting in accordance with Section 8(c) of the Plan. 

 

	 	•	 	 SIGNING BONUS. You shall be entitled to receive a signing bonus, equal to
$200,000, less applicable taxes and withholdings, payable in a single lump-sum cash payment within 30 days following your commencement of employment with the Company. In the event that your employment with the
Company terminates at any time within your first twelve months of active employment, either as the result of termination by the Company for Cause or by you other than for Good Reason (all determined in accordance with this Agreement), you shall be
required to repay to the Company, on a net after-tax basis (determined after taking into account available deductions), 100% of the Signing Bonus. Any amount required to be repaid shall be repaid to the
Company no later than 30 days following your termination of employment. 

  

	 	•	 	 RELOCATION ASSISTANCE. We recognize that you will need assistance for your
move from South San Francisco, CA, to San Diego, CA. We are offering you relocation assistance equal to $100,000, grossed up, payable in a single lump-sum cash payment within 30 days following your
commencement of employment with the Company. In the event that your employment with the Company terminates at any time within your first twelve months of active employment, either as the result of termination by the Company for Cause or by you other
than for Good Reason (all determined in accordance with this Agreement), you shall be required to repay to the Company, on a net after-tax basis (determined after taking into account available deductions),
100% of the amounts payable to you under this paragraph. Any amount required to be repaid shall be repaid to the Company no later than 30 days following your termination of employment. Any exceptions to the conditions outlined must be pre-approved by Human Resources. Please contact Lorraine Lockwood for additional assistance.  

  

	 	•	 	 BENEFITS. You shall be eligible to participate in all of the
employee benefit plans or programs the Company generally makes available to similarly situated employees, pursuant to the terms and conditions of such plans. You will initially be entitled to 18 days of paid time off each year (exclusive of any
Company shut down periods applicable to all employees), accruing on a semi-monthly basis, and all holidays observed by the Company each year. The Company reserves the right to change compensation and benefits provided to its employees from time to
time in its discretion. 

	 	•	 	 INDEMNIFICATION AGREEMENT. The Company will
enter into with you the Indemnification Agreement attached to this Agreement. In addition, the Company will maintain, at its sole expense, director and officer liability insurance covering you on the same basis as other executive officers. Your
rights under the Indemnification Agreement and herein are in addition to, and exclusive of, any rights you may have to indemnification, insurance coverage, or exculpation under the Company’s Bylaws, Articles of Incorporation or other organizing
documents or as otherwise provided by applicable law. 

  

	 	•	 	 WITHHOLDING. All amounts payable to you will be subject to appropriate payroll deductions
and withholdings. 

 • EXPENSES. You will be entitled to reimbursement for all ordinary and
reasonable out-of-pocket business expenses which are reasonably incurred by you in furtherance of the Company’s business, with appropriate documentation and in
accordance with the Company’s standard policies. 
 • SEVERANCE. 

 

	 	•	 	 ACCRUED OBLIGATIONS. If your employment terminates for any
reason, you are entitled to your fully earned but unpaid base salary, through the date such termination is effective at the rate then in effect, and all other amounts or benefits to which you are entitled under any compensation, retirement or
benefit plan of the Company at the time of your termination of employment in accordance with the terms of such plans, including, without limitation, any accrued but unpaid paid time off and any continuation of benefits required by applicable law
(the “Accrued Obligations”). 

  

	 	•	 	 NON-CIC SEVERANCE
BENEFITS. In addition to your Accrued Obligations, subject to your continued compliance with the Proprietary Information and Inventions Agreement, as described below, and the effectiveness of your Release (as
defined below), if your employment is involuntarily terminated by the Company without Cause (as defined below) (and other than by reason of your death or disability) or you resign for Good Reason (as defined below) (either such termination, a
“Qualifying Termination”), and such Qualifying Termination does not occur during the Change in Control Period (as defined below), you shall be entitled to receive, as the sole severance benefits to which you are entitled, the
benefits provided below (the “Non-CIC Severance Benefits”): 

  

	 	•	 	 An amount equal to your base salary for the Non-CIC Severance Period (as
defined below) (at the rate in effect immediately prior to the date of your termination of employment), payable in a lump sum on the first regularly-scheduled payroll date following the date your Release becomes effective (but in no event more than
75 days following your termination date). 

  

	 	•	 	 For the Non-CIC Severance Period (or, if earlier, the date on which the
applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or any similar local, state or federal law (“COBRA”) expires) (the “COBRA Coverage Period”),
if you and/or your eligible dependents who were covered under the Company’s health 

	 	 
insurance plans as of the date of your termination of employment elect to have COBRA coverage and are eligible for such coverage, the Company shall pay directly to the applicable plan
administrator an amount equal to the full monthly premium you and/or your covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for you and/or your eligible dependents, as applicable, who were covered
under the Company’s health plans as of the date of your termination of employment (calculated by reference to the premium as of the date of your termination of employment) . If any of the Company’s health benefits are self-funded as of the
date of your termination of employment, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), or that is
otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments as set forth above, the Company shall instead pay to you the foregoing monthly amount as a
taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). You shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such
coverage and the timely payment of premiums. You shall notify the Company immediately if you become eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment. 

 

	 	•	 	 CIC SEVERANCE BENEFITS. In addition to your Accrued
Obligations, subject to your continued compliance with the Proprietary Information and Inventions Agreement, as described below, and the effectiveness of your Release, if your Qualifying Termination occurs during the Change in Control Period, you
shall be entitled to receive, as the sole severance benefits to which you are entitled and in lieu of any Non-CIC Severance Benefits, the benefits provided below (the “CIC Severance
Benefits”) (and for the avoidance of doubt, in no event will you be entitled to both the Non-CIC Severance Benefits and the CIC Severance Benefits): 

 

	 	•	 	 An amount equal to your base salary for the CIC Severance Period (as defined below) (at the rate in effect
immediately prior to the date of your termination of employment), payable in a lump sum on the first regularly-scheduled payroll date following the date your Release becomes effective (but in no event more than 75 days following your termination
date). 

  

	 	•	 	 An amount equal to (a) (i) your Target Bonus Amount for the year in which your date of termination occurs,
divided by (ii) 12, multiplied by (b) the number of months in the CIC Severance Period, payable in a lump sum on the first regularly-scheduled payroll date following the date your Release becomes effective (but in no event more than 75 days
following your termination date). 

  

	 	•	 	 For the CIC Severance Period (or, if earlier, the date on which the applicable continuation period under COBRA
expires) (the “CIC COBRA Coverage Period”), if you and/or your eligible dependents who were covered under the Company’s health insurance plans as of the date of your termination of employment elect to have COBRA coverage
and are eligible for such coverage, the Company shall pay directly to the applicable plan 

	 	 
administrator an amount equal to the full monthly premium you and/or your covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for you and/or your
eligible dependents, as applicable, who were covered under the Company’s health plans as of the date of your termination of employment (calculated by reference to the premium as of the date of your termination of employment). If any of the
Company’s health benefits are self-funded as of the date of your termination of employment, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A of the Code, or that is otherwise compliant
with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to you the foregoing monthly amount as a
taxable monthly payment for the CIC COBRA Coverage Period (or any remaining portion thereof). You shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such
coverage and the timely payment of premiums. You shall notify the Company immediately if you become eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment. 

 

	 	•	 	 Notwithstanding anything else set forth herein, in the Plan or in any award agreement, 100% of any unvested Stock
Awards (as defined below) then held by you (including the Stock Options) will fully vest on the effective date of your Release. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision
in any agreement or plan regarding such Stock Award. 

  

	 	•	 	 The Company intends to review the severance arrangements for its executive officers in connection with any
initial public offering and to make adjustments to such provisions at that time based on market practice. 

  

	 	•	 	 As a condition to your receipt of any post-termination payments and benefits pursuant to the preceding
paragraphs, you shall execute and not revoke a general release of all claims in favor of the Company (the “Release”) in a form reasonably acceptable to the Company. The Release will not waive: (1) any rights to
indemnification and/or contribution, advancement or payment of related expenses you may have pursuant to the Company’s Bylaws or other organizing documents, under any written indemnification or other agreement between you and the Company,
and/or under applicable law; (2) any rights you may have to insurance coverage under any directors and officers liability insurance, other insurance policies of the Company, COBRA or any similar state law; (3) any claims for
worker’s compensation benefits, disability or unemployment insurance, or any other claims that cannot be released as a matter of applicable law; (4) your rights to any vested equity or vested benefits under any written agreement with the
Company or Company benefit plan, subject to the terms and conditions of such plan and applicable law; (5) your rights as an equity holder of the Company or any affiliates, if applicable; and (6) any claims arising after the date you sign
the Release. In the event the Release does not become effective within the 60-day period following the date of your termination of employment, you will not be entitled to the aforesaid payments and benefits.

	 	•	 	 For purposes of this Agreement, “Cause” means any of the following: (a) your
commission of an act of fraud, embezzlement or dishonesty, or the commission of some other illegal act by you, that has a demonstrable adverse impact on the Company or any successor or affiliate thereof; (b) your conviction of, or plea of
“guilty” or “no contest” to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (c) any intentional, unauthorized use or disclosure by you of
confidential information or trade secrets of the Company or any successor or affiliate thereof; (d) your gross negligence, insubordination or material violation of any duty of loyalty to the Company or any successor or affiliate thereof, or any
other demonstrable material misconduct on your part; (e) your ongoing and repeated refusal to perform your duties as required by this Agreement or your ongoing and repeated refusal to comply with the lawful instructions given to you by the
Chief Executive Officer of the Company or the Board; or (f) your willful, material breach of any Company policy or any material provision of this Agreement or the Proprietary Information and Inventions Agreement. Prior to the determination that
“Cause” under clauses (a), (c), (d), (e) or (f) has occurred, the Company shall (i) provide to you in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (ii) in the case of
clauses (d), (e) and (f), afford you a reasonable opportunity of not less than thirty days to remedy any such conditions, if capable of being cured, (iii) provide you an opportunity to be heard prior to the final decision to terminate your
employment hereunder for such “Cause” and (iv) make any decision that such “Cause” exists in good faith. The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or
affiliate thereof to discharge or dismiss you for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause. 

 

	 	•	 	 For purposes of this Agreement, “Change in Control” has the meaning set forth in the
Plan. 

  

	 	•	 	 For purposes of this Agreement, “Change in Control Period” means the period
commencing on the date of a Change in Control and ending 12 months following such Change in Control. 

  

	 	•	 	 For purposes of this Agreement, “CIC Severance Period” means 9 months.

  

	 	•	 	 For purposes of this Agreement, “Good Reason” means any of the following without your
written consent: (a) a material diminution in your authority, duties or responsibilities; (b) a material diminution in your base compensation, unless such a reduction is no more than 10% or is imposed across-the-board to all senior management of the Company; (c) following your relocation to the San Diego, California area, a material change in the geographic location at which you must perform your
duties (and you and the Company agree that a change of more than 35 miles shall be material for this purpose); provided, that in no event will your required relocation to the San Diego, California area constitute Good Reason hereunder; or
(e) any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to you under this Agreement or any other agreement between you and the Company or any of its affiliates. You
must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without your written consent within 90 days of the occurrence of such event. The Company or any successor or affiliate shall have a period of
30 days to cure such event or condition after receipt of written notice of such event from you. Your termination of employment by reason of resignation from employment with the Company for Good Reason must occur within 30 days following the
expiration of the foregoing 30-day cure period. 

	 	•	 	 For purposes of this Agreement, “Non-CIC Severance
Period” means, provided your Qualifying Termination does not occur during the Change in Control Period, 6 months. 

  

	 	•	 	 For purposes of this Agreement, “Stock Awards” means all stock options, restricted stock
and such other awards granted pursuant to the Plan or the Company’s other stock option and equity incentive award plans or agreements, as in effect from time to time, and any shares of stock issued upon exercise or settlement thereof, including
the Stock Options. 

  

	 	•	 	 To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code
and Department of Treasury regulations and other interpretive guidance issued thereunder. The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from Section 409A of the Code and, accordingly, to
the maximum extent permitted, this Agreement shall be interpreted to be in compliance with such intention. To the extent that any provision in this Agreement is ambiguous as to its compliance with or exemption from Section 409A of the
Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code. For purposes of Section 409A of the
Code, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. For purposes of this Agreement, to the extent that the payments or benefits under this Agreement are “non-qualified deferred compensation” subject to Section 409A of the Code or as otherwise required to ensure such payments or benefits are exempt from or comply with Section 409A of the Code, all
references to your “termination of employment” shall mean your “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h)) (“Separation from
Service”). If you are a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of your Separation from Service, to
the extent that the payments or benefits under this Agreement are “non-qualified deferred compensation” subject to Section 409A of the Code and the delayed payment or distribution of all or any
portion of such amounts to which you are entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this paragraph shall be paid or
distributed to you in a lump sum on the earlier of (a) the date that is 6 months and one day following your Separation from Service, (b) the date of your death or (c) the earliest date as is permitted under Section 409A of the
Code. Any remaining payments due under this Agreement shall be paid as otherwise provided herein. 

  

	 	•	 	 To the extent that the payments or benefits under this Agreement are
“non-qualified deferred compensation” subject to Section 409A of the Code, if the period during which you may deliver the Release required hereunder spans two calendar years, the payment of your
post-termination benefits shall occur on the later of (a) January 1 of the second calendar year, or (b) the first regularly-scheduled payroll date following the date your Release becomes effective. 

	 	•	 	 Any reimbursement of expenses or in-kind benefits payable under this
Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of your taxable year following the taxable year in which you
incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable in one year shall not affect the amount eligible for reimbursement or in-kind
benefits payable in any other taxable year of yours, and your right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. 

 

	 	•	 	 If either you or the Company reasonably determines that any payment or benefit will violate Section 409A of
the Code, you and the Company will use best efforts to restructure the payment in a manner that is either exempt from or compliant with Section 409A of the Code. You and the Company agree to execute any and all amendments to this Agreement
or any other agreement as may be necessary to ensure compliance with the distribution provisions of Section 409A of the Code in an effort to avoid or minimize, to the extent allowable by law, the tax (and any interest or penalties thereon)
associated with Section 409A of the Code. If it is determined that a payment or benefit was (or may be) made in violation of Section 409A of the Code, the Company will cooperate reasonably with any effort you undertake to mitigate the
tax consequences of such violation, including cooperation with your participation in any IRS voluntary compliance program or other correction procedure under Section 409A of the Code that may be available to you. 

• SECTION 280G TREATMENT. 

 

	 	•	 	 In the event that any payment or benefit received or to be received by you pursuant to the terms of any plan,
arrangement or agreement (including any payment or benefit received in connection with a change of control or the termination of your employment) (all such payments and benefits being hereinafter referred to as the “Total
Payments”) would be subject (in whole or part) to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no portion
of the Total Payments is subject to the Excise Tax but only if (a) the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after taking into
account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (b) the net amount of such Total Payments without such reduction (after subtracting the net amount of
federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which you would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal
exemptions attributable to such unreduced Total Payments); provided, however, that this sentence shall not apply if, immediately before the change in ownership or control on which such Total Payments are contingent or otherwise relate,
no stock in the Company is readily tradeable on an established securities market or otherwise (as determined in accordance with Treasury Reg. Section 1.280G-1 Q&A 6). The Total Payments shall be
reduced in the following order: (i) reduction of any cash severance payments otherwise payable to you that are exempt from Section 409A of the Code, (ii) reduction of any other cash payments or benefits otherwise payable to you that
are exempt from Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of
the 

	 	 
Code, (iii) reduction of any other payments or benefits otherwise payable to you on a pro-rata basis or such other manner that complies with
Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting and payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of the Code, and
(iv) reduction of any payments attributable to the acceleration of vesting or payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of the Code; provided, in case of
clauses (ii), (iii) and (iv), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time. The foregoing
reductions shall be made in a manner that results in the maximum economic benefit to you on an after-tax basis and, to the extent economically equivalent payments or benefits are subject to reduction, in a pro
rata manner. 

  

	 	•	 	 All determinations regarding the application of this “Section 280G Treatment” section shall be
made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax
retained by the Company prior to the date of the applicable change in control (the “280G Firm”). For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (a) no
portion of the Total Payments shall be taken into account which, in the written opinion of the 280G Firm, (i) does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of
Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base
amount” (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation, (b) no portion of the Total Payments the receipt or enjoyment of which you shall have waived at such time and in such manner as not to
constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken into account, and (c) the value of any non-cash benefit or any deferred payment or benefit included
in the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4) of the Code. All determinations related to the calculations to be performed pursuant to this this
“Section 280G Treatment” section shall be done by the 280G Firm. 

  

	 	•	 	 The 280G Firm will be directed to submit its determination and detailed supporting calculations to both you and
the Company within 15 days after notification from either the Company or you that you may receive payments which may be “parachute payments.” You and the Company will each provide the 280G Firm access to and copies of any books, records,
and documents in their possession as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The
fees and expenses of the 280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. 

 

	 	•	 	 Notwithstanding the foregoing, if any portion of the Total Payments would not be subject to the Excise Tax if the
stockholder approval requirements of Section 280G(b)(5) of the Code are satisfied, subject to your waiver of the rights to such portion of the Total Payments above the safe harbor threshold in accordance with

	 	 
and to the extent required by Section 280G of the Code with respect to any portion of the Total Payments that would otherwise be subject to excise tax imposed by Section 4999 of the
Code (before giving effect to any reduction in the Total Payments contemplated above), the Company shall use its reasonable best efforts to cause such payments to be submitted for such approval prior to the event giving rise to such payments. To the
extent the Company submits any payment or benefit payable to you under this Agreement or otherwise to the Company’s stockholders for approval in accordance with Treasury Reg. Section 1.280G-1 Q&A
7, the foregoing provisions under this “Section 280G Treatment” section shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction
in, or waiver above the safe harbor threshold of, such payments or benefits required by such vote will be applied without any application of discretion by you and in the order prescribed in the preceding paragraph. 

 

	 	•	 	 COMPANY POLICIES AND PROPRIETARY
INFORMATION AND INVENTIONS AGREEMENT. As an employee of the Company, you shall be expected to abide by all of the Company’s policies and procedures and the Company’s employee
handbook, if any. As a condition of your continued employment, you agree to execute and abide by the terms of the Company’s form of Proprietary Information and Inventions Agreement, which shall survive termination of your employment with the
Company and the termination of this Agreement. You acknowledge that a remedy at law for any breach or threatened breach by you of the provisions of the Proprietary Information and Inventions Agreement would be inadequate, and you therefore agree
that the Company shall be entitled to seek injunctive relief in case of any such breach or threatened breach. The Company may modify, revoke, suspend or terminate any of the terms, plans, policies and/or procedures described in the employee
handbook, if any, or as otherwise communicated to you, in whole or part, at any time, with or without notice. Notwithstanding the foregoing, or anything contained in the Proprietary Information and Inventions Agreement, (a) as used in the
Proprietary Information and Inventions Agreement, “Proprietary Information” shall not include any information that was known to you or lawfully in your possession before any disclosure of such information to you by the Company or is
lawfully disclosed to you by any third parties that are unrelated to the Company and are not bound by obligations of confidentiality with respect thereto; and (b) following your termination of employment, you may retain, in hardcopy and/or
electronic format, any contact information maintained by you as of your last day of employment with the Company. Nothing in this Agreement or the Proprietary Information and Inventions Agreement will prohibit you from disclosing Proprietary
Information to the extent compelled by law, regulation, court order, or other governmental authority; provided, however, that you shall, to the extent possible and permissible under applicable law, first give the Company prompt notice and cooperate
reasonably with the Company in any proceeding to obtain a protective order or other remedy. If such protective order or other remedy is not obtained, you shall only disclose that portion of such Proprietary Information required to be disclosed, in
the opinion of your legal counsel. Compulsory disclosures made pursuant to this paragraph shall not relieve you of your obligations of confidentiality and non-use with respect to
non-compulsory disclosures. In addition, you acknowledge that you will not be held criminally or civilly liable for (i) the disclosure of confidential or proprietary information that is made in confidence
to a government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) disclosure of confidential or proprietary information made in a complaint or other document filed in a lawsuit
or other proceeding under seal or pursuant to court order. 

 • EMPLOYMENT
TERMS. As a condition to your employment with the Company, you are required to (a) sign and return a satisfactory I-9 Immigration form providing sufficient
documentation establishing your employment eligibility in the United States, and (b) provide satisfactory proof of your identity as required by United States law. This offer is also contingent upon (c) a successful completion of a
background check and positive references. 

 • OTHER AGREEMENTS. You represent and agree that
your performance of your duties for the Company shall not violate any agreements, obligations or understandings that you may have with any third party or prior employer. You agree not to make any unauthorized disclosure or use, on behalf of the
Company, of any confidential information belonging to any of your former employers. You also represent that you are not in unauthorized possession of any materials containing a third party’s confidential and proprietary information. While
employed by the Company, you will not engage in any business activity in competition with the Company nor make preparations to do so. In the event that you wish to undertake a business activity outside the scope of your employment by the Company,
which activity you believe entails no conflict with the Company’s activities, you agree to inform the Company of your intentions prior to the initiation of such outside business activity, and you furthermore agree to abide by the Company’s
decision as to whether or not there is no conflict. If, in the Company’s sole determination, a conflict exists or is likely to develop, you agree not to undertake such outside business activity. 

• AT-WILL EMPLOYMENT. Your employment with
the Company will be “at-will” at all times, including after your introductory, probationary period, meaning that either you or the Company will be entitled to terminate your employment at any time
and for any reason, with or without Cause. Any contrary representations that may have been made to you are superseded by this offer. This Agreement in no way represents a fixed-term employment contract. This is the full and complete agreement
between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment
may only be changed in an express written agreement signed by you and a duly authorized officer of the Company. 
 •
NON-INTERFERENCE. While employed by the Company, and for one year immediately following the date on which you terminate employment or otherwise cease providing services to
the Company, you agree not to interfere with the business of the Company by (a) soliciting or attempting to solicit any employee or consultant of the Company to terminate such employee’s or consultant’s employment or service in order
to become an employee, consultant or independent contractor to or for any other person or entity or (b) soliciting or attempting to solicit any vendor, supplier, customer or other person or entity either directly or indirectly, to direct his,
her or its purchase of the Company’s products and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company. Your duties under this paragraph shall survive termination of your
employment with the Company and the termination of this Agreement. 
 • DISPUTE
RESOLUTION. Unless otherwise prohibited by law or specified below, all disputes, claims and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or
interpretation shall be resolved solely and exclusively by final and binding arbitration held in San Diego, California, before a single, mutually-agreed neutral arbitrator, through Judicial Arbitration & Mediation Services/Endispute
(“JAMS”) under the then existing JAMS arbitration rules. The rules may be found online at www.jamsadr.com or upon written request to the Company. This paragraph is intended to be the exclusive method for resolving any
and all claims by the parties against each other relating to your employment; provided that you will retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to
participate in any government investigation, including but not limited to (a) claims for workers’ compensation, state disability insurance or unemployment insurance; (b) claims for unpaid wages or waiting time penalties brought before
the California Division of Labor Standards Enforcement (provided that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this paragraph; and (c) claims
for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair Employment and Housing (or any similar agency in any applicable 

 
jurisdiction other than California); provided, further, that, except as otherwise provided by law, you will not be entitled to obtain any monetary relief through such agencies other
than workers’ compensation benefits or unemployment insurance benefits. Further, nothing in this paragraph is intended to prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any
such arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure §1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall
not be deemed to be a waiver of such party’s right to compel arbitration. In resolving any matter submitted to arbitration, the arbitrator will strictly follow the substantive law applicable to the dispute, claim or controversy and the
arbitrator’s authority and jurisdiction will be limited to determining the dispute in conformity with applicable law as to liability, damages and remedies, to the same extent as if the dispute was determined by a court without a jury. The
arbitrator will issue a written decision that contains the essential findings of fact and conclusions of law on which the decision is based, which may be entered as a judgment in any court of competent jurisdiction. The Company shall pay all costs
of arbitration, including without limitation, arbitration administrative fees, arbitrator compensation and expenses, and costs of any witnesses called by the arbitrator. Unless otherwise ordered by the arbitrator under applicable law, the Company
and you shall each bear its or your own expenses, such as attorneys’ fees, costs and disbursements. The prevailing party in any arbitration or other dispute between the parties will be entitled to an award of attorneys’ fees and costs, in
addition to any other relief. Each party warrants that it has had the opportunity to be represented by counsel in the negotiation and execution of this Agreement, including the attorneys’ fees provision herein. Both you and the Company
expressly waive your right to a jury trial. You further waive your right to pursue claims against the Company on a class basis; provided, however, that you do not waive your right, to the extent preserved by law, to pursue representative claims
against the Company under the California Private Attorney General Act. 
 •
SEVERABILITY. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held
to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein. 

• SUCCESSORS AND ASSIGNS. This Agreement is intended to
bind and inure to the benefit of and be enforceable by you and the Company, and their respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any of your
rights hereunder, without the written consent of the Company, which shall not be withheld unreasonably. The Company will require any successors or assigns to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession or assignment had taken place. 
 •
ENTIRE AGREEMENT. This Agreement, the Indemnification Agreement, the Proprietary Information and Inventions Agreement and other documents referenced herein and therein constitute the complete, final and exclusive
embodiment of the entire agreement between you and the Company with respect to the terms and conditions of your employment specified herein and therein, and supersede any other such promises, warranties, representations or agreements between you and
the Company. This Agreement may not be amended or modified except by a written instrument signed by you and a duly authorized officer of the Company. 

• GOVERNING LAW. This Agreement will be governed by and construed in accordance with the laws of the
State of California without regard to the conflicts of law provisions thereof. 

 If you choose to accept this Agreement under the terms described above, please acknowledge
your acceptance of our offer by returning a signed copy of this letter, the Indemnification Agreement, and the Proprietary Information and Inventions Agreement to our attention. 

Sincerely, 
 Erasca, Inc. 

 

			
	 /s/ Jonathan Lim

	Name:	 	Jonathan Lim
	Title:	 	Chairman and CEO

 Agreed and Accepted:  

I have read and understood this Agreement and hereby acknowledge, accept and agree to the terms as set forth above and further acknowledge and
agree that no other commitments were made to me as part of my employment offer except as specifically set forth herein.  
  

							
	 /s/ Wei Lin
	 		  	 November 6, 2020
	  	
	WEI LIN	 	                	  	DATE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]